XML 149 R42.htm IDEA: XBRL DOCUMENT
v3.25.1

Contingencies and commitments (Details) - USD ($) $ in Thousands | Mar. 31, 2025 | Dec. 31, 2024 | Mar. 31, 2024 | Dec. 31, 2023 | Oct. 31, 2014
--- | --- | --- | --- | --- | ---
Contingencies and Commitments [Line Items] |  |  |  |  |
Fair value of contingent consideration | $ 10,524 | $ 10,225 | $ 7,780 | $ 7,600 |
Recurring |  |  |  |  |
Contingencies and Commitments [Line Items] |  |  |  |  |
Fair value of contingent consideration | 10,524 | $ 10,225 |  |  |
Enantigen's Selling Shareholders | Recurring |  |  |  |  |
Contingencies and Commitments [Line Items] |  |  |  |  |
Fair value of contingent consideration | $ 10,500 |  |  |  | $ 0
Enantigen's Selling Shareholders | Arbutus Inc. |  |  |  |  |
Contingencies and Commitments [Line Items] |  |  |  |  |
Development and regulatory milestones payment per licensed compound series, maximum |  |  |  |  | 102,500
Development and regulatory milestones payment per royalty, maximum |  |  |  |  | $ 1,000

X
- References No definition available. + Details
Name: | abus_ContingenciesandCommitmentsLineItems
Namespace Prefix: | abus_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition License Agreement, Maximum Development and Regulatory Milestone Payments Per License + References No definition available. + Details
Name: | abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense
Namespace Prefix: | abus_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition License Agreement Maximum Development And Regulatory Royalty Payment per Royalty + References No definition available. + Details
Name: | abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerRoyalty
Namespace Prefix: | abus_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=abus_EnantigensSellingShareholdersMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=abus_EnantigensSellingShareholdersMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=abus_ArbutusInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |